Loading company…
Reverb Therapeutics develops bispecific antibodies intended to enhance immune responses.
Reverb Therapeutics develops bispecific antibodies through its Amplify·R platform, which is designed to amplify natural cytokine signaling. Its programs target potential applications in malignancies and autoimmune diseases. Founded in 2023, the company is based in Vancouver, Canada, and raised USD 12 million in Seed funding in February 2025, led by Amplitude, with Myeloma Investment Fund, KdT Ventures, Finchley Healthcare Ventures, InBC Investment and Seido Capital participating.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in